Tyrosine News and Research

RSS

DeepTarget tool uncovers primary and secondary drug targets across cancer types

One person's side effect could be another person's treatment if we expand our perspective on small molecule drug targets, according to a new study published November 5, 2025, in npj Precision Oncology.

18 Nov 2025

DeepTarget: A new tool for drug repurposing in oncology

14 Nov 2025

High protein breakfasts help you feel fuller but do not change how much you eat later

High protein breakfasts, whether plant or animal-based, boosted GLP-1 and PYY and modestly reduced appetite compared with a low protein, high carbohydrate meal. Despite these hormonal and appetite changes, lunchtime energy intake remained unchanged in both younger and older adults.

13 Nov 2025

St. Jude study maps treatment strategy for rare infant gliomas

Clinician-scientists at St. Jude Children's Research Hospital and collaborators have conducted the largest study of infant-type hemispheric glioma (IHG) ever reported, uncovering key factors that could be used to guide treatment strategies for this rare pediatric brain tumor.

11 Nov 2025

New NIH grants fuel research in oral cancer treatment and pain relief

Researchers at the School of Dentistry at UT Health San Antonio, the academic health center of The University of Texas at San Antonio, have been awarded three multi-year grants totaling $6 million from the National Institutes of Health to address treatment and pain management for oral cancer.

7 Nov 2025

Comprehensive kinase atlas reveals new insights into cell signaling and disease

The enzyme RNA polymerase II transcribes genes into messenger RNA. This process is guided by modifications to the enzyme's "tail" called phosphorylation patterns.

7 Nov 2025

Alzheimer’s breakthrough reveals how tweaking one gene shields brain connections

Lowering the transcription factor PU.1 reprograms microglia into a neuroprotective, lymphoid-like state that compacts amyloid, blocks tau spread, and preserves synapses in Alzheimer’s disease. Microglial CD28 signaling helps restrain inflammation, revealing a regulatory switch that may inform future immunotherapies targeting microglia rather than neurons.

6 Nov 2025

Combination therapy offers hope for ending lifelong chronic lymphocytic leukemia treatment

Ianalumab targets the B-cell activating factor receptor (BAFR) and ibrutinib belongs to a class of therapeutics called Bruton's tyrosine kinase inhibitors (BTKi).

6 Nov 2025

Sensory effects of flavanols trigger physiological responses in the brain

Astringency is a dry, puckering, rough, or sandpapery sensation in the mouth caused by plant-derived polyphenols.

31 Oct 2025

Eating peanuts while pregnant may influence how a child’s genes respond to breastfeeding

Maternal peanut and peanut butter consumption during pregnancy and breastfeeding shaped DNA methylation patterns in children, particularly in genes regulating neurodevelopment and inflammation. These findings suggest maternal diet can prime offspring epigenetic sensitivity to breastfeeding duration.

27 Oct 2025

Oral targeted therapy shrinks tumors in over 70% of patients with HER2-mutant NSCLC

The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant non-small cell lung cancer (NSCLC), according to data from a trial led by researchers at The University of Texas MD Anderson Cancer Center.

22 Oct 2025

Tracking daily blood pressure in pregnancy could predict low birth weight sooner

Early-pregnancy home blood pressure patterns reveal that even small cumulative elevations, not just high averages, raise the risk of low birth weight. Tracking daily readings above thresholds may improve early warning and maternal–fetal outcomes.

21 Oct 2025

Belzutifan demonstrates strong clinical activity in two rare neuroendocrine tumors

A multicenter Phase II clinical trial led by researchers at The University of Texas MD Anderson Cancer Center demonstrated significant tumor shrinkage and disease control in patients with advanced pheochromocytoma and paraganglioma (PPGL), two rare and potentially life-threatening neuroendocrine tumors.

18 Oct 2025

Osimertinib plus chemotherapy improves survival in EGFR-mutated lung cancer

Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival in patients with newly diagnosed EGFR-mutated advanced non-small cell lung cancer (NSCLC) compared to osimertinib alone.

17 Oct 2025

Common food additives may trigger childhood asthma

Researchers utilize metabolomics to investigate the mechanisms underlying the association between food additives and childhood asthma.

6 Oct 2025

Dipeptides reveal clues to the origin of life’s instructions

Genes are the building blocks of life, and the genetic code provides the instructions for the complex processes that make organisms function.

17 Sep 2025

HIIT boosts anti-cancer proteins and slows breast cancer growth

Both resistance training and HIIT enhance myokine levels and suppress breast cancer cell growth, supporting exercise as a therapeutic strategy for survivors.

15 Sep 2025

Osimertinib plus chemotherapy offers overall survival advantage for patients with EGFR-mutated advanced NSCLC

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).

8 Sep 2025

Ivonescimab plus chemotherapy provides survival benefit for difficult-to-treat NSCLC patients

Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations whose disease progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs).